|
Post by lsl428 on Apr 20, 2017 9:02:17 GMT -5
with MNKD now at 100 million market cap......the Valencia property sale represents basically 17 percent of that number .....Wow......so the Danbury plant ...what is that worth? We have to be getting to a ridiculously low Market cap even intrinsically speaking I guess barring BK......where creditors are very secure in that collateral i would have to think.
I think there is a lien on that property but not an outstanding note? That state of the art facility is owned outright by MNKD? Just creating more discussion
|
|
|
Post by mnkdnewb on Apr 20, 2017 9:47:02 GMT -5
IMO, this is why they did a 5:1 reverse split. The bare bones value of mannkind is probably right around $75,000,000 in a bk sale which would put them at about $1 per share (maybe a tad under). If scripts go up they will be ok with Nasdaq, if they don't then the $1 per share minimum doesn't matter anyways as they will bk.
|
|
|
Post by scoy on Apr 20, 2017 10:30:08 GMT -5
As part of the huge write-off at the end of 2015 they wrote off the much of the value of the property in Danbury.
The Danbury property (or properties) has a 28.7 million dollar mortgage and also is (part of) the security for the Deerfield loan.
In my opinion the current stock price reflects the current Afrezza sales rate, and the current (and future) sales by the company of shares.
And lastly the cost of a company is not just its shares (101 million times 1.07). It's the shares, plus all of its money owed.
|
|
|
Post by matt on Apr 20, 2017 10:42:24 GMT -5
with MNKD now at 100 million market cap......the Valencia property sale represents basically 17 percent of that number .....Wow......so the Danbury plant ...what is that worth? We have to be getting to a ridiculously low Market cap even intrinsically speaking I guess barring BK......where creditors are very secure in that collateral i would have to think. I think there is a lien on that property but not an outstanding note? That state of the art facility is owned outright by MNKD? Just creating more discussion The lien on Danbury secures the Deerfield notes, so it is essentially like a mortgage. The problem with pharmaceutical manufacturing plants is that they have very little value in the resale market because they are designed and constructed to produce a particular product, and reconfiguring a plant and validating a new production line is time consuming and expensive. There is no shortage of nearly new, and a few absolutely brand new, pharmaceutical plants that you can buy for pennies, and gently used manufacturing equipment has a resale value in the range of 10 to 15 cents on the dollar. That seems like a ridiculously low number, but since a pharma manufacturing process are designed and validated with particular equipment, most companies won't buy used equipment unless it is exactly the same brand and model number as what they already have because revalidating is more expensive than the extra cost of buying new equipment. Danbury only has significant value in the hands of the entity that owns the patents needed to make Afrezza, provided however, that they want to continue making Afrezza in that location. In the hands of any other owner the facility is just another commercial structure looking for a new use.
|
|
|
Post by therealisaching on Apr 20, 2017 10:59:04 GMT -5
As part of the huge write-off at the end of 2015 they wrote off the much of the value of the property in Danbury. The Danbury property (or properties) has a 28.7 million dollar mortgage and also is (part of) the security for the Deerfield loan. In my opinion the current stock price reflects the current Afrezza sales rate, and the current (and future) sales by the company of shares. And lastly the cost of a company is not just its shares (101 million times 1.07). It's the shares, plus all of its money owed. 100MM & 150MM in debt to acquire 100%. Hard to believe.
|
|
|
Post by radgray68 on Apr 20, 2017 12:21:26 GMT -5
As part of the huge write-off at the end of 2015 they wrote off the much of the value of the property in Danbury. The Danbury property (or properties) has a 28.7 million dollar mortgage and also is (part of) the security for the Deerfield loan. In my opinion the current stock price reflects the current Afrezza sales rate, and the current (and future) sales by the company of shares. And lastly the cost of a company is not just its shares (101 million times 1.07). It's the shares, plus all of its money owed. 100MM & 150MM in debt to acquire 100%. Hard to believe. And we're still at about 10x sales, which is pricey for any company without growth. Hard to believe is right
|
|
|
Post by buyitonsale on Apr 20, 2017 13:01:49 GMT -5
And we also have that FDA approved drug with patents worldwide.
|
|